RetinaCME
VIDEOCMEABO MOC

Lengthening the Treatment Interval in Age-related Macular Degeneration: Current Status and Insights

Author(s)/Faculty: Carl D. Regillo, MD; Rishi P. Singh, MD
Release Date: 6/30/2021Expiration Date: 6/29/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: VideoProvider:
Intravitreal antivascular endothelial growth factor therapy has revolutionized the treatment of neovascular age-related macular degeneration (nAMD), but the burden of treatment created by frequent intraocular injections is high. Ongoing research is examining the safety and efficacy of agents with extended duration of action as well as drug delivery systems that reduce treatment burden. Through education on these ongoing developments, clinicians will be better poised to deliver timely, optimized care. In this continuing medical education activity, expert faculty assess new evidence regarding the use of novel delivery systems and agents with increased duration of action that have the potential to improve outcomes for patients with nAMD.